Cystostatic Checkpoint Therapy
Tau Therapeutics is a development stage biopharmaceutical company built on a revolutionary discovery of a Cytostatic Checkpoint Therapy™ that inhibits the growth of cancer cells.Tau was formed to address the growing need for a new and different way of treating cancer. Tau’s vision of cancer treatment is one of personalized chronic maintenance. Tau believes it is positioned to be at the forefront of cancer treatment and is the world leader in developing calcium T-channel blockers for oncology and other diseases. At Tau, we believe the future in cancer treatment will be to stop the growth of cancer cells prior to forming tumors and metastasizing. This will be the revolution in cancer treatment.
At Tau, the revolution in cancer means a personalized approach to cancer treatment with:- Early detection through diagnostic screening of calcium T-Channel
- Biopsy Tumor for expression of target
- Prescribe a chronically administered pill that inactivates the target
- Treats cancer like any other chronic disease
- Targeted therapy – very limited side effects
- Maintenance therapy to control (not kill) cancer
- Least expensive means of treating cancer
- Extends length and quality of life
An Evolution in the War on Cancer
The mission of Tau is to transform the very nature of how we treat cancer - from late stage treatments such as toxic chemotherapy, radiation, and surgery to a therapeutic daily regime similar to the way we treat hypertension for early to late stage cancer. Tau's goal is to usher in the next, and hopefully final, generation of cancer treatments - a new approach to cytostatic chemotherapy. The company is focused on the research, development, repositioning and commercialization of calcium T-channel therapeutics.
Tau’s technology is centered on modulating the calcium ion dependent mechanisms critical to cell proliferation. Tau has applied for and been granted patent protection on this unique target, on diagnostic testing utilizing the target gene or protein, and on several chemical classes that inhibit the target in order to offer patients a personalized approach to treating cancer.
Tau’s researchers are working toward developing a diagnostic test that detects the presence of cancer at the very earliest stages. It is also creating simple compounds that can be prescribed on a daily basis for multiple cancer types.Tau plans to position itself to develop a platform approach for cancer and other proliferative diseases.
LEARN MORE ››